How DEA’s proposal will affect telehealth controlled substance prescribing

The latest stories trending on MedCity News.

Editor's Pick

Top Story 'The Stakes Couldn't Be Higher': How DEA's Proposal Will Affect Telehealth Controlled Substance Prescribing The DEA recently released proposed rules that would require an in-person visit before a patient can receive a telehealth prescription for a controlled substance. The DEA touts the change as a way to ensure patient safety, but several telehealth advocates argue it will greatly disrupt access for those who need the drugs — especially at a time when the mental health and substance use crisis is growing. Network with the Best in Healthcare and Save $600 Now that spring has officially arrived, it's time to get out and network with the best of the best in 5-star luxury and convenience. Register Today and Save $600!

Featured News

StartUp Health Gains a New Investor and Adds a University StartUp Health's presence at ViVE will highlight the launch of its Health Transformer University and the addition of Helmsley Charitable Trust as an investor. Its pavilion will showcase 16 health tech companies and include panel discussions on remote patient monitoring, automation and more. "Culling of the Herd": How One CEO Believes SVB's Failure May Accelerate M&A in Healthtech Included Health CEO Owen Tripp believes that the sudden demise of Silicon Valley Bank may actually lead to a "culling of the herd" as healthtech companies yet to prove their value will stop functioning as standalone companies or get bought by larger companies with stable revenue and a proven business model. FDA Warning Letter Issued to Website Purveying Ivermectin Pills for Covid-19 The FDA has issued a warning letter to a website that has been selling the antiparasitic drug ivermectin as a treatment for Covid-19. The correspondence directs the company to stop selling its products and correct any misleading language in its marketing material. Nvidia, Medtronic Partner to Create AI Platform for Medical Devices Nvidia and Medtronic recently announced a collaboration focused on embedding AI into medical devices. The two companies plan to create marketplace for AI applications that will allow developers and clinicians to develop their own algorithms to use on Medtronic's medical devices. Allermi Raises $3.5M in Seed Funding To Grow DTC Allergy Relief Platform Allermi's $3.5 million seed funding was led by Nelstone Ventures and included participation from FourSight Capital Partners. The company will use the money to expand nationally. Sobi and Selecta Bio Gout Drug Hits Phase 3 Goals, Paving Way for FDA Submission Sobi said it plans to seek FDA approval of the gout drug, SEL-212, in 2024. If approved, it would compete against Krystexxa, a Horizon Therapeutics drug projected to become a blockbuster seller. Pharmacists Are Essential to Rural Access to Healthcare Tapping into community pharmacy can bring water to these rural healthcare deserts. Studies show that nine in ten Americans live within five miles of a pharmacy and high-risk patients visited their community pharmacy an average of 35 times per year, compared to four visits to their primary care provider and nine visits to specialists.

Resources

How Top Health Plans Use AI to Save Money and Work Smarter Learn how an AI-powered solution helped Blue Cross Blue Shield of Rhode Island target members within its congestive heart failure (CHF) and spinal care (MSK) programs to identify avoidable hospitalizations and drive significant cost savings. Download Now

MedCity News • 611 Broadway • New York, NY unsubscribe